Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 13, 2026, 5:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 363 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Red Blood Cells Clear all
Completed No phase listed Observational Accepts healthy volunteers

Quantitative Susceptibility Mapping (QSM) to Guide Iron Chelating Therapy

NCT04171635
View directory record Official record
Conditions
MRI Scans
Interventions
Quantitative Susceptibility Mapping (QSM) Magnetic Resonance Imaging (MRI), R2* Magnetic Resonance Imaging (MRI)
Radiation
Lead sponsor
Weill Medical College of Cornell University
Other
Eligibility
2 Years and older
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
2
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Expanded Access of Deferasirox to Patients With Congenital Disorders of Red Blood Cells and Chronic Iron Overload

NCT00235391
View directory record Official record
Conditions
Thalassemia, Sickle Cell Disease, Diamond Blackfan Anemia, Myelofibrosis
Interventions
Deferasirox
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
2 Years and older
Enrollment
1,683 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2008
U.S. locations
27
States / cities
Little Rock, Arkansas • Berkeley, California • Orange, California + 23 more
Source: ClinicalTrials.gov public record
Updated Jun 6, 2011 · Synced Sep 13, 2026, 5:51 PM EDT
Not listed Not applicable Interventional

Autologous Peripheral Blood Stem Cell Transplantation in Patients With Life Threatening Autoimmune Diseases

NCT00006055
View directory record Official record
Conditions
Purpura, Schoenlein-Henoch, Graft Versus Host Disease, Anemia, Hemolytic, Autoimmune, Rheumatoid Arthritis, Churg-Strauss Syndrome, Hypersensitivity Vasculitis, Wegener's Granulomatosis, Systemic Lupus Erythematosus, Giant Cell Arteritis, Pure Red Cell Aplasia, Juvenile Rheumatoid Arthritis, Polyarteritis Nodosa, Autoimmune Thrombocytopenic Purpura, Takayasu Arteritis
Interventions
anti-thymocyte globulin, cyclophosphamide, cyclosporine, filgrastim, methylprednisolone, prednisone, Autologous Peripheral Blood Stem Cell Transplantation
Drug · Procedure
Lead sponsor
Fairview University Medical Center
Other
Eligibility
1 Year to 55 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jun 23, 2005 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Efficacy Study of Stearidonic Acid (SDA) Soybean Oil-containing Foods on Red Blood Cell Fatty Acid Content

NCT01369550
View directory record Official record
Conditions
Healthy Volunteers, Markers of Cardiovascular Risk
Interventions
SDA soybean oil-containing foods, High-oleic sunflower oil containing foods, Eicosapentaenoic acid
Other
Lead sponsor
Monsanto Company, LLC
Industry
Eligibility
21 Years to 65 Years
Enrollment
127 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
2
States / cities
St. Petersburg, Florida • Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Jun 8, 2011 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety Study of ECO Conversion System For Red Blood Cells.

NCT00261274
View directory record Official record
Conditions
Anemia
Interventions
A-ECO, Saline
Biological
Lead sponsor
Velico Medical
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2005
U.S. locations
6
States / cities
New Haven, Connecticut • Minneapolis, Minnesota • Albuquerque, New Mexico + 3 more
Source: ClinicalTrials.gov public record
Updated May 26, 2020 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

BioRBC Survival in Adults With Prior Antibody Response to BioRBCs

NCT02077751
View directory record Official record
Conditions
Anemia
Interventions
biotin labelled RBCs
Drug
Lead sponsor
John A Widness
Other
Eligibility
18 Years to 99 Years
Enrollment
3 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2019
U.S. locations
1
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated Apr 28, 2021 · Synced Sep 13, 2026, 5:51 PM EDT
Terminated Phase 2 Interventional Results available

Study to Evaluate Effect of a Single Dose of Sotatercept (ACE-011) on Red Blood Cell Mass and Plasma Volume in Participants With Solid Tumors

NCT01190644
View directory record Official record
Conditions
Solid Tumors
Interventions
Sotatercept
Drug
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
3
States / cities
Baltimore, Maryland • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Efficacy and Safety Study for an Oral Contraceptive Containing Folate

NCT00468481
View directory record Official record
Conditions
Neural Tube Defects, Contraception, Oral Contraceptives (OC)
Interventions
Drospirenone/Ethinylestradiol/Methyltetrahydrofolate, Drospirenone/Ethinylestradiol (Yaz)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years to 40 Years · Female only
Enrollment
385 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2007 – 2008
U.S. locations
9
States / cities
Anaheim, California • San Diego, California • Baltimore, Maryland + 6 more
Source: ClinicalTrials.gov public record
Updated Apr 22, 2014 · Synced Sep 13, 2026, 5:51 PM EDT
Terminated Phase 3 Interventional Results available

A Study of a Single Dose of Inclacumab to Reduce Re-admission in Participants With Sickle Cell Disease and Recurrent Vaso-occlusive Crises

NCT04927247
View directory record Official record
Conditions
Sickle Cell Disease, Vaso-occlusive Crisis, Vaso-occlusive Pain Episode in Sickle Cell Disease
Interventions
Inclacumab, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
12 Years and older
Enrollment
72 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
17
States / cities
Mobile, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 10, 2024 · Synced Sep 13, 2026, 5:51 PM EDT
Recruiting Not applicable Interventional

Bladder Cancer Screening Trial

NCT05646485
View directory record Official record
Conditions
Bladder Cancer, Urothelial Carcinoma, Hematuria, Smoking Cessation
Interventions
Urinalysis
Diagnostic Test
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
50 Years and older
Enrollment
1,000 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Apr 30, 2026 · Synced Sep 13, 2026, 5:51 PM EDT
Terminated Phase 1 Interventional Results available

Pilot Lenalidomide in Adult Diamond-Blackfan Anemia Patients w/ RBC Transfusion-Dependent Anemia

NCT01034592
View directory record Official record
Conditions
Anemia, Leukemia, Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS)
Interventions
Lenalidomide
Drug
Lead sponsor
Jason Robert Gotlib
Other
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2017 · Synced Sep 13, 2026, 5:51 PM EDT
Withdrawn Phase 3 Interventional

H-36731: Finasteride in Management of Elevated Red Blood Cells

NCT02548117
View directory record Official record
Conditions
ERYTHROCYTOSIS
Interventions
Finasteride
Drug
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older · Male only
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Dec 15, 2019 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Not applicable Interventional

Assessing the Feasibility of a Novel Non-Invasive Sensor for Guiding Wounded Warrior Rehabilitation

NCT02887755
View directory record Official record
Conditions
Rehabilitation Post-amputation
Interventions
Near-Infrared Spectroscopy (NIRS) Sensor
Device
Lead sponsor
Henry M. Jackson Foundation for the Advancement of Military Medicine
Other
Eligibility
18 Years to 45 Years
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2017
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Apr 1, 2018 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Myocardial Ischemia and Transfusion

NCT02981407
View directory record Official record
Conditions
Myocardial Infarction, Anemia
Interventions
Red Blood Cell Transfusion
Biological
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
3,506 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
60
States / cities
Little Rock, Arkansas • Los Angeles, California • Danbury, Connecticut + 48 more
Source: ClinicalTrials.gov public record
Updated May 8, 2024 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Early Phase 1 Interventional Results available

A Dose-Finding Study of AG-348 in Sickle Cell Disease

NCT04000165
View directory record Official record
Conditions
Sickle Cell Disease
Interventions
AG-348
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 11, 2022 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Not applicable Interventional

Blood Volume and Hemodynamic Analysis in Patients With Chronic Heart Failure

NCT02120014
View directory record Official record
Conditions
Congestive Heart Failure
Interventions
blood volume measurement, venous plethysmography
Procedure
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 23, 2018 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 3 Interventional Results available

Study to Evaluate the Efficacy & Safety of the INTERCEPT Blood System for RBCs in Complex Cardiac Surgery Patients

NCT03459287
View directory record Official record
Conditions
Anemia
Interventions
INTERCEPT, Control
Device
Lead sponsor
Cerus Corporation
Industry
Eligibility
11 Years and older
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
18
States / cities
Los Angeles, California • Stanford, California • Aurora, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 13, 2026, 5:51 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Consortium for Optimized Integration of Bio-Artificial Blood Components for Adaptive Resuscitation Therapy

NCT05756426
View directory record Official record
Conditions
Hemorrhage, Hemodynamic Instability
Interventions
Prospective
Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years to 88 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2029
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Sep 13, 2026, 5:51 PM EDT
Recruiting Phase 2 Interventional

Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells

NCT01174108
View directory record Official record
Conditions
Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)
Interventions
Miltenyi CD34 Reagent System, Donor derived G-CSF mobilized PBC
Device · Other
Lead sponsor
National Heart, Lung, and Blood Institute (NHLBI)
NIH
Eligibility
4 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2028
U.S. locations
2
States / cities
Baltimore, Maryland • Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 17, 2026 · Synced Sep 13, 2026, 5:51 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Off-pump Versus On-pump Coronary Artery Bypass Grafting in Frail Patients

NCT02338947
View directory record Official record
Conditions
Frail Elderly, Coronary Artery Disease
Interventions
Off-pump coronary-artery bypass grafting, On-pump coronary-artery bypass grafting
Other
Lead sponsor
University of Sao Paulo General Hospital
Other
Eligibility
60 Years and older
Enrollment
440 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 13, 2026, 5:51 PM EDT
Enrolling by invitation Not applicable Interventional

Implementation of Red Blood Cell Transfusion Recommendations in the Pediatric Intensive Care Unit

NCT07108374
View directory record Official record
Conditions
Red Blood Cell Transfusions
Interventions
Implementation strategies to increase use of transfusion recommendations
Other
Lead sponsor
Stanford University
Other
Eligibility
Not listed
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
2
States / cities
Palo Alto, California • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Aug 6, 2025 · Synced Sep 13, 2026, 5:51 PM EDT
Not listed Phase 1Phase 2 Interventional Accepts healthy volunteers

ASIS for Enbrel in Plaque Psoriasis

NCT02112097
View directory record Official record
Conditions
Plaque Psoriasis.
Interventions
Gadolinium, Efficacy of Enbrel subcutaneously at Week 12, Efficacy of Enbrel subcutaneously at Week 24, Efficacy of Enbrel subcutaneously at Week 36, Efficacy of Enbrel subdermally at Week 12, Efficacy of Enbrel subdermally at Week 24, Efficacy of Enbrel subdermally at Week 36, PASI 75 n(%) subcutaneously at Week 12, PASI 75 n(%) subcutaneously at Week 24, PASI 75 n(%) subcutaneously at Week 36, PASI 75 n(%) subdermally at Week 12, PASI 75 n(%) subdermally at Week 24, PASI 75 n(%) subdermally at Week 36, Adverse Reactions of Enbrel subcutaneously, Adverse Reactions of Enbrel subdermally at Week 36
Drug
Lead sponsor
ASIS Corporation
Industry
Eligibility
21 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Westminster, California
Source: ClinicalTrials.gov public record
Updated Jun 23, 2015 · Synced Sep 13, 2026, 5:51 PM EDT
Completed Phase 3 Interventional

Premature Infants in Need of Transfusion (PINT)

NCT00182390
View directory record Official record
Conditions
Anemia of Prematurity
Interventions
Red blood cell transfusion
Procedure
Lead sponsor
McMaster University
Other
Eligibility
Up to 48 Hours
Enrollment
424 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2005
U.S. locations
2
States / cities
Albany, New York • Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Sep 23, 2015 · Synced Sep 13, 2026, 5:51 PM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Blood Sampling for Research Related to Sickle Cell Disease

NCT00542230
View directory record Official record
Conditions
Sickle Cell Trait, Sickle Cell Disease, Sickle Cell Anemia
Interventions
Not listed
Lead sponsor
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
Eligibility
18 Years to 100 Years
Enrollment
250 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2007
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 13, 2026, 5:51 PM EDT